Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

February 17, 2020February 17, 2020

New Variant in RELN Gene Linked to AS in Iranian Family

News

A new genetic variant in the RELN gene was identified in ankylosing spondylitis (AS) patients in the same family, an Iranian study reports. The study, “Identification of RELN varient p.(Ser2486Gly) ... Read more

January 13, 2020January 13, 2020

Levels of DNASE1L3 Protein Are Potential Biomarker of Ankylosing Spondylitis, Study Suggests

News

Analyzing the levels of a protein called DNASE1L3 may enable an accurate diagnosis of ankylosing spondylitis (AS), a study suggests. Besides being able to distinguish between AS and generalized ... Read more

December 9, 2019December 9, 2019

FDA Approves Avsola, Remicade Biosimilar, to Treat Active Ankylosing Spondylitis

News

The U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq), a biosimilar to Remicade (infliximab), to treat active ankylosing spondylitis, its maker, Amgen, announced. The new therapy has been ... Read more

December 5, 2019December 5, 2019

Taltz Eases Disease Activity, Improves Quality of Life in nr-axSpA Patients, Phase 3 Trial Shows

News

Treatment with the anti-rheumatic drug Taltz (ixekizumab) leads to early and sustained reductions in pain, fatigue, and inflammation in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial ... Read more

November 25, 2019November 25, 2019

Cosentyx Reduces Disease Activity and Pain in nr-axSpA Patients, Phase 3 Trial Shows

News

Treatment with Cosentyx (secukinumab) provided stable reduction in disease activity, as well as less pain and better mobility in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial ... Read more

November 7, 2019November 7, 2019

Continuous Use of NSAIDs Increases Hypertension Risk in AS Patients, Study Suggests

News

Continuous use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hypertension by 12% in people with ankylosing spondylitis (AS), a prospective study suggests. The study, “Nonsteroidal Anti-inflammatory Drug ... Read more

November 4, 2019November 4, 2019

Women Stop Using TNF Inhibitors Earlier and Switch More Often Than Do Men, Dutch Study Reports

News

Women with ankylosing spondylitis (AS) stay with TNF inhibitor treatment for significantly shorter periods than men, mostly due to ineffectiveness, and they are at higher risk of developing infections while on ... Read more

October 21, 2019October 21, 2019

Xeljanz Reduces Spinal Inflammation in One-third of AS Patients, Phase 2 Trial Shows

News

Treatment with Xeljanz (tofacitinib citrate) led to a clinically meaningful reduction in spinal and sacroiliac joint inflammation in approximately one-third of ankylosing spondylitis (AS) patients taking part in a ... Read more

October 7, 2019October 7, 2019

Cosentyx Effectively Lowers Disease Activity in nr-axSpA Patients Treated for 1 Year, Phase 3 Trial Reports

News

Treatment with Novartis’ Cosentyx (secukinumab) significantly reduced disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to new data from the Phase 3 PREVENT trial. The ... Read more

Pin It on Pinterest